Photo from wikipedia
The role of pre‐hematopoietic stem cell transplantation (HSCT) cytoreduction with either induction chemotherapy (IC) or hypomethylating agents (HMAs) in treating advanced myelodysplastic syndrome (MDS) remains debatable. We aimed to evaluate… Click to show full abstract
The role of pre‐hematopoietic stem cell transplantation (HSCT) cytoreduction with either induction chemotherapy (IC) or hypomethylating agents (HMAs) in treating advanced myelodysplastic syndrome (MDS) remains debatable. We aimed to evaluate pre‐HSCT strategies by comparing the endpoints related to disease control between advanced MDS patients with pre‐HSCT cytoreduction and those with best supportive care.
Keywords:
advanced myelodysplastic;
pre transplantation;
myelodysplastic syndrome;
transplantation;
cytoreduction
Journal Title: Cancer Communications
Year Published: 2021
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!
Journal Title: Cancer Communications
Year Published: 2021
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!